MindMaze Therapeutics Holding (XSWX:MMTX) Debt-to-Asset : 0.04 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MMTX MindMaze Therapeutics Holding SA XSWX:MMTX
4 GF Score
Price CHF0.18
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding Debt-to-Asset?

MindMaze Therapeutics Holding XSWX:MMTX +3.33% 4 Debt-to-Asset is 0.04 as of Dec. 2025. GuruFocus rates XSWX:MMTX with a GF Score™ of 4/100. The stock has 2 warning signs investors should review.

MindMaze Therapeutics Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was CHF0.63 Mil. MindMaze Therapeutics Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was CHF1.18 Mil. MindMaze Therapeutics Holding's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2025 was CHF51.53 Mil. MindMaze Therapeutics Holding's debt to asset for the quarter that ended in Dec. 2025 was 0.04.

MindMaze Therapeutics Holding  (XSWX:MMTX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

MindMaze Therapeutics Holding Debt-to-Asset Related Terms

MindMaze Therapeutics Holding Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding Debt-to-Asset Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
Debt-to-Asset
0.00 0.04

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Dec25
Debt-to-Asset 0.00 0.04

XSWX:MMTX vs VRTX, REGN, MRNA: Debt-to-Asset Comparison

For the Biotechnology subindustry, MindMaze Therapeutics Holding's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindMaze Therapeutics Holding Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where MindMaze Therapeutics Holding's Debt-to-Asset falls into.


XSWX:MMTX
4GF Score
MindMaze Therapeutics Holding SA XSWX:MMTX
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

MindMaze Therapeutics Holding's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.629 + 1.177) / 51.53
=0.04

MindMaze Therapeutics Holding's Debt-to-Asset for the quarter that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.629 + 1.177) / 51.53
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.04 mean?
MindMaze Therapeutics Holding (XSWX:MMTX) has a Debt-to-Asset of 0.04 as of Dec. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on MindMaze Therapeutics Holding and its competitors.
Is MindMaze Therapeutics Holding's Debt-to-Asset too high?
MindMaze Therapeutics Holding's current Debt-to-Asset is 0.04. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Debt-to-Asset compare to VRTX and REGN?
MindMaze Therapeutics Holding's Debt-to-Asset of 0.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current Debt-to-Asset is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current Debt-to-Asset of 0.04. The current Debt-to-Asset is 0.04. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current Debt-to-Asset is 0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Other Exchanges RLFTY:USAMMTXz:UK
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score

Get the complete analysis for XSWX:MMTX

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF0.18
Price